The use of radiotherapy in non-gastric intestinal mucosa-associated lymphoid tissue (MALT) lymphoma should result in good local control and long-term survival, according to a study.
Although radiotherapy is used often in patients with gastric MALT lymphomas who fail to respond to Helicobacter pylori eradication, no standard therapeutic strategy is established for patients with non-gastric intestinal MALT.
In this study, 34 patients with stage I EA gastrointestinal MALT lymphoma who underwent definitive radiotherapy were included. The primary site was in the stomach in 30 patients, in the rectum in 3, and the duodenum in 1.
All patients had a complete response, with no local recurrences. Recurrence at other sites were found in 2 cases. The 5-year overall survival rates for non-gastric MALT lymphomas and gastric MALT lymphomas were 100% and 94.7%, respectively, with 5-year disease-free survival rates if 100% and 95.7%, respectively.
Watanabe S, Ogino I, Hata M. Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes. Blood Res. 2020; DOI: 10.5045/br.2020.2020174. Epub ahead of print. PMID: 33139588.